SapVax was founded in January 2017, based on breakthrough peptide chemistry and immunological insights.

SapVax is developing powerful therapeutic cancer vaccines based on a proprietary platform for coupling tumor-specific peptides to our novel series of immunostimulatory adjuvants to create fully-synthetic, self-adjuvanting cancer vaccines. SapVax’s platform has the potential to generate a robust pipeline of novel vaccines.

SapVax is a BioMotiv portfolio company and is supported by several investors.

Company Mission & Values

Mission: SapVax is dedicated to developing a portfolio of safe and effective cancer vaccines with superior tumor-clearing properties for patients in need through partnerships and ongoing collaborations.

Values: Dedication, Accountability, and Trust - Mutual Respect and Empowerment - Clear and Honest Communication

Scientific Founders

Leadership Team